|
1
|
Komatsu SI, Watanabe H, Oka T, Tsuge H,
Nii H and Kato N: Vitamin B-6-supplemented diets compared with a
low vitamin B-6 diet suppress azoxymethane-induced colon
tumorigenesis in mice by reducing cell proliferation. J Nutr.
131:2204–2207. 2001.PubMed/NCBI
|
|
2
|
Komatsu S, Watanabe H, Oka T, Tsuge H and
Kato N: Dietary vitamin B6 suppresses colon tumorigenesis,
8-hydroxyguanosine, 4-hydroxynonenal, and inducible nitric oxide
synthase protein in azoxymethane-treated mice. J Nutr Sci
Vitaminol. 48:65–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ishihara J, Otani T, Inoue M, Iwasaki M,
Sasazuki S and Tsugane S; Japan Public Health Center-based
Prospective Study Group. Low intake of vitamin B-6 is associated
with increased risk of colorectal cancer in Japanese men. J Nutr.
137:1808–1814. 2007.PubMed/NCBI
|
|
4
|
Theodoratou E, Farrington SM, Tenesa A, et
al: Dietary vitamin B6 intake and the risk of colorectal cancer.
Cancer Epidemiol Biomarkers Prev. 17:171–182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Larsson SC, Orsini N and Wolk A: Vitamin
B6 and risk of colorectal cancer: a meta-analysis of prospective
studies. JAMA. 303:1077–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang XH, Ma J, Smith-Warner SA, Lee JE
and Giovannucci E: Vitamin B6 and colorectal cancer:
current evidence and future directions. World J Gastroenterol.
19:1005–1010. 2013.
|
|
7
|
Yanaka N, Koyama TA, Komatsu S, Nakamura
E, Kanda M and Kato N: Vitamin B6 suppresses NF-κB
activation in LPS-stimulated mouse macrophages. Int J Mol Med.
16:1071–1075. 2005.
|
|
8
|
Matsubara K, Mori M, Matsuura Y and Kato
N: Pyridoxal 5′-phosphate and pyridoxal inhibit angiogenesis in
serum-free rat aortic ring assay. Int J Mol Med. 8:505–508.
2001.
|
|
9
|
Komatsu S, Yanaka N, Matsubara K and Kato
N: Antitumor effect of vitamin B6 and its mechanisms.
Biochim Biophys Acta. 1647:127–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kayashima T, Tanaka K, Okazaki Y,
Matsubara K, Yanaka N and Kato N: Consumption of vitamin
B6 reduces colonic damage and protein expression of
HSP70 and HO-1, the anti-tumor targets, in rats exposed to
1,2-dimethylhydrazine. Oncol Lett. 2:1243–1246. 2011.
|
|
11
|
Zhang PP, Suidasari S, Hasegawa T, Yanaka
N and Kato N: High concentrations of pyridoxal stimulate the
expression of IGFBP1 in HepG2 cells through upregulation of the
ERK/c-Jun pathway. Mol Med Rep. 8:973–978. 2013.PubMed/NCBI
|
|
12
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deiry WS, Tokino T, Velculescu VE, et al:
WAF1, a potential mediator of p53 tumor suppression. Cell.
75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakari M, Kanouchi H and Oka T: High dose
of pyridoxine induces IGFBP-3 mRNA expression in MCF-7 cells and
its induction is inhibited by the p53-specific inhibitor
pifithrin-α. J Nutr Sci Vitaminol. 57:280–284. 2011.PubMed/NCBI
|
|
15
|
Masisi K, Suidasari S, Zhang P, Okazaki Y,
Yanaka N and Kato N: Comparative study on the responses of
concentrations of B6-vitamers in several tissues of mice
to the dietary level of pyridoxine. J Nutr Sci Vitaminol.
58:446–451. 2012.PubMed/NCBI
|
|
16
|
Reeves GP, Nielsen HF and Fahey CG Jr:
AIN-93 purified diets for laboratory rodents: Final report of the
American Institute of Nutrition ad hoc writing committee on
the reformulation of the AIN-76A rodent diet. J Nutr.
123:1939–1951. 1993.PubMed/NCBI
|
|
17
|
Kanouchi H, Shibuya M, Tsukamoto S,
Fujimura Y, Tachibana H, Yamada K and Oka T: Comparisons of uptake
and cell surface binding among pyridoxal, pyridoxine, and
pyridoxamine in RAW264.7 cells. Nutrition. 26:648–652. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakurai T, Asakura T, Mizuno A and Matsuda
M: Absorption and metabolism of pyridoxamine in mice. I Pyridoxal
as the only form of transport in blood. J Nutr Sci Vitaminol.
37:341–348. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pasz-Walczak G and Kordek R: Comparative
evaluation of the expression of cell cycle regulating proteins:
cyclin D1, P53 and P21 (WAF1) in colorectal cancer. Pol J Pathol.
51:63–69. 2000.PubMed/NCBI
|
|
20
|
King ML and Murphy LL: Role of cyclin
inhibitor protein p21 in the inhibition of HCT116 human colon
cancer cell proliferation by American ginseng (Panax
quinquefolius) and its constituents. Phytomedicine. 17:261–268.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Volakaki AA, Lafkas D, Kassi E, Schally
AV, Papavassiliou AG and Kiaris H: Essential role of p21/waf1 in
the mediation of the anti-proliferative effects of GHRH antagonist
JMR-132. J Mol Endocrinol. 41:389–392. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang WC, Mathew J, Velcich A, et al:
Targeted inactivation of the p21(WAF1/cip1) gene enhances
Apc-initiated tumor formation and the tumor-promoting activity of a
Western-style high-risk diet by altering cell maturation in the
intestinal mucosal. Cancer Res. 61:565–569. 2001.PubMed/NCBI
|
|
23
|
Poole AJ, Heap D, Carroll RE and Tyner AL:
Tumor suppressor functions for the Cdk inhibitor p21 in the mouse
colon. Oncogene. 23:8128–8134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang W, Velcich A, Lozonschi I, et al:
Inactivation of p21WAF1/cip1 enhances intestinal tumor
formation in Muc2−/− mice. Am J Pathol. 166:1239–1246.
2005.PubMed/NCBI
|
|
25
|
Zirbes TK, Baldus SE, Moenig SP, et al:
Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J
Cancer. 89:14–18. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vitiello PF, Wu YC, Staversky RJ and
O’Reilly MA: p21(Cip1) protects against oxidative stress by
suppressing ER-dependent activation of mitochondrial death
pathways. Free Radic Biol Med. 46:33–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Komarova EA, Krivokrysenko V, Wang K, et
al: p53 is a suppressor of inflammatory response in mice. FASEB J.
19:1030–1032. 2005.PubMed/NCBI
|
|
28
|
Kawauchi K, Araki K, Tobiume K and Tanaka
N: Loss of p53 enhances catalytic activity of IKKbeta through
O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci
USA. 106:3431–3436. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scatizzi JC, Mavers M, Hutcheson J, et al:
The CDK domain of p21 is a suppressor of IL-1beta-mediated
inflammation in activated macrophages. Eur J Immunol. 39:820–825.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trakala M, Arias CF, García MI, et al:
Regulation of macrophage activation and septic shock susceptibility
via p21(WAF1/CIP1). Eur J Immunol. 39:810–819. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
|
